Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Phase 3RecruitingNCT04161053

Tanta University60 enrolled

Overview

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Hepatic Encephalopathy

Interventions

RifaximinDRUG

Rifaximin 550 mg twice daily for 6 months

NitazoxanideDRUG

Nitazoxanide 500 mg twice daily for 6 months

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cirrhotic patient with at least one previous episode of hepatic encephalopathy. * Adult Patients aging from 20 to 65 years old Exclusion Criteria: * Active GIT bleeding. * Major psychiatric illness (psychosis \& epilepsy). * Renal insufficiency (S.Cr 2mg/dl).

Locations (1)

Sherief Abd-Elsalam

Tanta, Egypt

RECRUITING

Outcomes

Primary Outcomes

Number of encephalopathy episodes during treatment

The number of encephalopathy episodes during treatment

Time frame: 6 months

Central Contacts

Sherief Abd-Elsalam, ass. prof.

CONTACT

00201147773440 sheriefabdelsalam@yahoo.com

sherief abd-elsalam, ass. prof.

CONTACT

00201147773440 sherif_tropical@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.